Impact of Trans-catheter Aortic Valve Implantation on Renal Function
Recruiting now
Conditions studied: Aortic Valve Stenosis, Chronic Kidney Diseases, Renal Failure Acute Chronic
In brief
Both contrast-induced acute kidney injury (AKI) and pre-existing chronic kidney disease are associated with an increased mortality risk in patients requiring aortic valve replacement. Nonetheless, the direct haemodynamic impact of the aortic barrage (i.e. pre-renal mechanism) on renal function compromising and its reversibility in patients undergoing trans-catheter aortic valve implantation (TAVI) is unknown. This registry aims to evaluate the effect of severe aortic stenosis removal on the risk of contrast-induced acute renal injury (CI-AKI) during TAVI procedures and on renal function evolution
Key facts
- Study ID
- NCT07626710
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- People needed
- 1000
- Starts
- 2024-08-30
- Expected to finish
- 2033-08-30
- Last updated by the study team
- 2026-06-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age >18 years with a life expectancy >1 year;
- Patient candidate for percutaneous aortic valve implantation after formal indication of our "Heart Team".
- Patient performed at least one contrast-based exam other than the TAVI procedure in the previous two months.
- Patients had adequate renal function assessment after each contrast medium administration (TAVI procedure included) with at least three post-procedural measurements in the following 5 days.
- Patients were informed of the possibility to be the object of anonymized data collection for study protocols approved by the internal Ethical Committee and had provided written informed consent to the procedure (for patients before 2018) or had provided written informed consent to the research purposes of IRCCS (for patients from 2018 to date).
You may not qualify if…
- Female with childbearing potential or lactating;
- Acute or chronic end-stage renal dysfunction defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2);
- Candidate for dialysis treatment;
- Co-morbidities that could interfere with the completion of study procedures, or life expectancy of less than 1 year;
- Absent or incomplete renal function assessment after each contrast-based procedure;
- Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study;
Where it is running
- Enrico Romagnoli — Roma, RM, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.